New combo therapy aims to shrink sarcomas
NCT ID NCT06113809
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether giving a targeted drug (palbociclib) before immunotherapy (pembrolizumab) is safe and can help shrink tumors in people with certain soft tissue sarcomas. About 8 participants will receive the combination. The main goal is to check for side effects and find the right dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALVEOLAR SOFT PART SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Iowa Hospitals & Clinics
RECRUITINGIowa City, Iowa, 52242, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Can engineered immune cells tackle childhood sarcoma?
- Can a new immunotherapy combo shrink Hard-to-Treat tumors?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?